Compare American Superconductor Corporation (AMSC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs Moderna, Inc. — how do they compare? American Superconductor Corporation trades at $32.35 (market cap $1.56B), while Moderna, Inc. trades at $63.78 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 15.5× American Superconductor Corporation's market cap, and Moderna, Inc. is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.
| AMSC | MRNA | |
|---|---|---|
Market Cap | $1.56B | $24.18B |
Sector | Technology | Health |
52-Week High | $66.68 | $81.80 |
52-Week Low | $25.95 | $22.36 |
Enterprise Value | $1.42B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $33.19, up 7.1% today, showing strong momentum despite a bearish technical signal. The company reported record Q1 2026 revenue of $94.1 million, up 30% year-over-year, but missed earnings estimates due to margin pressure. Analyst consensus leans bullish with 53% buy ratings, while technical indicators show resistance at $34 and support at $30.
Outlook remains mixed with strong revenue growth and record backlog providing visibility, but margin compression and aggressive valuation pose risks. The stock offers growth potential in energy infrastructure markets, though investors should monitor execution on profitability targets amid increasing competition.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
